Novo Nordisk's reign as Europe's most valuable company is facing a challenge from US rival Eli Lilly. Lilly's weight-loss ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first ... Zepbound, similar ...

India’s apex drug regulating authority, the Central Drugs Standard Control Organisation (CDSCO), has approved 19 new drugs so ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

FDA approves Zepbound for sleep apnoea, a weight-loss medication that improves OSA symptoms in obese patients.

Washington: US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss ...

U.S. regulators have approved the first drug treatment for sleep apnea, allowing the use of a weight-loss medication to ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...